All In MedTech

Regulatory pathways

What is PMA? FDA premarket approval for Class III devices

PMA FDA premarket approval explained: which devices need it, what the application contains, how review works, and the PMA supplement types after approval.

By the All In MedTech editorial team · Published November 19, 2026 · 6 min read

Premarket approval (PMA) is FDA's review process for Class III medical devices, the highest-risk category. Unlike a 510(k), a PMA does not rely on comparison to an existing device: the applicant must provide valid scientific evidence that the device is safe and effective for its intended use. A device can only be marketed after FDA issues an approval order.

PMA rests on section 515 of the Federal Food, Drug, and Cosmetic Act and the regulations in 21 CFR Part 814. FDA describes it as the most stringent type of device marketing application. This post explains which devices need one, what goes into it, how review works, and how changes are handled after approval.

Which devices need a PMA

A device needs a PMA when it is in Class III. Under 21 CFR 860.3, that is the class for devices where general and special controls are not enough to give reasonable assurance of safety and effectiveness, and the device is life-supporting or life-sustaining, is of substantial importance in preventing impairment of human health, or presents a potential unreasonable risk of illness or injury.

In practice that covers devices such as implantable cardiac devices, heart valves, many neurostimulators and some high-risk diagnostic tests. A device also lands in Class III by default if it is new, has no predicate, and cannot be classified into Class I or II through De Novo.

There is one historical wrinkle. Some Class III device types were on the market before May 28, 1976, and for years were cleared through 510(k) until FDA issued a regulation calling for PMAs. FDA has worked through most of these, but it explains why a few Class III product codes show 510(k) decisions in the public record.

What goes into a PMA application

The contents are listed in 21 CFR 814.20. The main parts are:

  1. A summary of the indications, the device, alternative treatments, marketing history and the key study results and conclusions.
  2. A complete device description, including components, properties, principles of operation, and the methods, facilities and controls used in manufacturing.
  3. Applicable performance standards and how the device meets them.
  4. Technical sections with nonclinical laboratory studies (such as bench, animal, biocompatibility, software and reliability testing) and the results of clinical investigations.
  5. Proposed labeling, including the instructions for use.
  6. Other items such as a bibliography, financial disclosure for clinical investigators, information about pediatric use, and an environmental assessment or claim of exclusion.

The clinical section is usually the largest part. Most original PMAs rest on at least one pivotal clinical study run under an Investigational Device Exemption, designed with FDA input to show the device's effectiveness and characterize its risks. You can find many of these studies on ClinicalTrials.gov or through the site's trials search.

Modular PMA

Instead of sending everything at once, a sponsor can split the application into modules, for example preclinical testing, manufacturing and clinical data, and submit each when it is ready. FDA reviews modules as they arrive, and the final module completes the application. This lets review of early sections proceed while the clinical study finishes.

How FDA reviews a PMA

The review runs in several stages:

  1. Filing review. FDA decides whether the application is complete enough to file. It will refuse to file an application missing required elements.
  2. In-depth scientific and regulatory review. Reviewers in engineering, clinical, statistics, biocompatibility, software and other disciplines evaluate the data, often sending deficiency letters.
  3. Advisory panel (when used). FDA can refer an application to an outside advisory committee of clinicians, scientists and patient and industry representatives, who discuss the data in a public meeting and vote on questions about safety, effectiveness and benefit-risk. The panel advises; FDA decides.
  4. Inspections. FDA normally inspects manufacturing facilities for compliance with quality system requirements before approval, and may audit clinical study sites.
  5. Decision. Under 21 CFR 814.44 and 814.45, FDA issues an approval order, an approvable letter, a not approvable letter, or an order denying approval.

The regulation at 21 CFR 814.40 gives FDA 180 days from filing to act, and a major amendment from the applicant extends that period. Real timelines are measured against user fee performance goals negotiated under the Medical Device User Fee Amendments. Those goals and the PMA user fee change between agreements and fiscal years. Check FDA's MDUFA page for current figures.

The approval standard

The legal test is reasonable assurance of safety and effectiveness, judged against the valid scientific evidence in the application and weighing probable benefits against probable risks. That is a higher and different bar from substantial equivalence. A PMA approval is FDA's own finding about the device, which is why "approved" is the correct word for PMA devices and "cleared" is the word for 510(k) devices. For the side-by-side comparison, see 510(k) vs De Novo vs PMA.

After approval: conditions and reports

Approval comes with obligations. The approval order can impose conditions of approval, including post-approval studies to answer questions about long-term performance, under 21 CFR 814.82. Holders must submit periodic reports, usually annually, under 21 CFR 814.84, and remain subject to adverse event reporting, recalls and inspections like every other manufacturer.

PMA supplements

Most changes to an approved device that affect safety or effectiveness need FDA approval before they are made, through a PMA supplement. FDA's PMA supplements page lists the types, which differ by how significant the change is:

Supplement typeUsed for
Panel-track supplementA significant change in design or performance, or a new indication for use, that needs substantial clinical data. Reviewed much like an original PMA and may go to an advisory panel.
180-day supplementSignificant changes to components, materials, design, specifications, software, color additives or labeling, usually supported by new preclinical data rather than new clinical data.
Real-time supplementMinor changes, such as to design, software, sterilization or labeling, reviewed jointly by FDA and the sponsor in a meeting or similar setting.
Special PMA supplement, changes being effectedChanges that improve safety, such as added warnings or added quality controls, which can be made once FDA confirms the supplement qualifies.
30-day notice and 135-day supplementChanges to manufacturing procedures or methods. The change may proceed after 30 days unless FDA finds the notice inadequate, in which case it becomes a 135-day supplement.
Manufacturing site change supplementMoving manufacturing, processing or packaging to a facility not covered by the approval.

Some minor changes can be reported in the annual report, and changes that do not affect safety or effectiveness may only need internal documentation. A change to intended use, mode of operation or technological basis can be large enough to require a new original PMA.

Supplements explain why the public PMA record for a long-marketed device can show hundreds of entries under one P number. Each supplement number (for example S001, S002) is a separate FDA decision on the same base application.

  • Humanitarian Device Exemption (HDE): for devices treating or diagnosing conditions affecting small populations. The applicant must show safety and probable benefit rather than effectiveness. It is governed by subpart H of Part 814.
  • Product Development Protocol (PDP): an alternative in the statute in which FDA and the sponsor agree in advance on the development plan. It is rarely used.
  • Breakthrough Devices Program: many PMA devices hold breakthrough designation, which brings more frequent interaction with FDA and priority review. See /breakthrough.

Reading the PMA record

FDA's PMA database lists each original application and supplement with the P number, applicant, device name, product code, decision date and supplement type. For original approvals, FDA posts a Summary of Safety and Effectiveness Data (SSED), which describes the clinical study design, patient population, results and FDA's benefit-risk reasoning. The SSED is the best single public source for understanding why a Class III device was approved. Pair it with MAUDE adverse event data and recall history to see how the device has performed since.

Frequently asked questions

What is a PMA?
A premarket approval application is FDA's review of a Class III device, in which the applicant must provide valid scientific evidence that the device is safe and effective for its intended use before it can be marketed.
Which devices need a PMA?
Class III devices generally need a PMA, along with high-risk novel devices that are not substantially equivalent to a predicate and cannot be placed in Class I or II through De Novo.
What is a panel-track supplement?
It is a PMA supplement for a significant change in design or performance, or a new indication for use, that needs substantial clinical data and may be reviewed by an advisory panel.
How long does FDA have to review a PMA?
The regulation at 21 CFR 814.40 gives FDA 180 days from filing, while actual timing is tracked against user fee performance goals that change with each MDUFA agreement.

For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.

Keep reading